Optimal use of NRTTI + NNRTI regimens in routine clinic practice - Anton Pozniak, MD, FRCP
Understanding and Managing Multi-Class Resistance | Anton Pozniak, MD, FRCPПодробнее
Newer NNRTI Agents in Clinical PracticeПодробнее
Long acting HIV drugs for treatment: what are the data? | Anton Pozniak, MD, FRCPПодробнее
Clinical Review: New RT inhibitors – Doravirine - Chloe Orkin, MBChB, FRCP, MDПодробнее
Q&A | Anton Pozniak, MD, FRCPПодробнее
Optimizing Clinical Utility of Integrase Inhibitors | Anton Pozniak, MD, FRCPПодробнее
PrEP: who, when and how | Anton Pozniak, MD, FRCPПодробнее
Mechanisms of Action: NRTI, NRTTI, and NNRTI - Carlo Federico PernoПодробнее
Session I - Managing Complex HIV Patients - European EditonПодробнее
IAS 2015 Anton PozniakПодробнее
Implementing First Day Treatment in Europe: Western Perspective | Margaret Johnson, MD, FRCPПодробнее
Update on Pharmacologic Options for HIV Prevention | Nittaya Phanuphak, MD, PhDПодробнее
Managing the Care of Patients Who Are Highly Treatment Experienced With Limited Treatment OptionsПодробнее
Dr. Anton Pozniak - Clinical Service Director, HIV. Chelsea and Westminster Hospital, London.Подробнее
La caractérisation des profils de résistance sélectionnés par la DoravirineПодробнее
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future | Session 2Подробнее
Clinical Advances in the management of HIV guidelines and New EvidenceПодробнее
NNRTI Resistance 2015Подробнее
